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SUMMARY
The antitumorigenic activity of antioxidants has been presumed to arise from their ability to squelch
DNA damage and genomic instability mediated by reactive oxygen species (ROS). Here, we report
that antioxidants inhibited three tumorigenic models in vivo. Inhibition of a MYC-dependent human
B lymphomamodel was unassociated with genomic instability but was linked to diminished hypoxia-
inducible factor (HIF)-1 levels in a prolyl hydroxylase 2 and von Hippel-Lindau protein-dependent
manner. Ectopic expression of an oxygen-independent, stabilized HIF-1 mutant rescued lymphoma
xenografts from inhibition by two antioxidants: N-acetylcysteine and vitamin C. These findings
challenge the paradigm that antioxidants diminish tumorigenesis primarily through decreasing
DNA damage andmutations and provide significant support for a key antitumorigenic effect of dimin-
ishing HIF levels.INTRODUCTION
Tumorigenesis resulting frommultistep activation of onco-
genes, loss of tumor suppressors, and adaptation to the
tumor microenvironment is thought to be in part driven
by genomic instability resulting from oxidative DNA dam-
age. In fact, a number of animal models suggest that anti-
oxidants could diminish tumorigenesis by suppressing
DNA damage and genomic instability. For example, loss
of ATM accelerates transgenic murine lymphomagenesis
in a fashion that is suppressible by N-acetylcysteine
(NAC), a well-established antioxidant that has been pre-
viously shown to diminish oxidative DNA modifications230 Cancer Cell 12, 230–238, September 2007 ª2007 Elsevier(Aitio, 2006; Reliene et al., 2004; Reliene and Schiestl,
2006). This claim has been bolstered by a study of
a p53-dependent mouse lymphomagenesis model in
which NAC slowed tumor progression seemingly by re-
ducing genomic instability (Sablina et al., 2005). Further-
more, NAC has been used clinically in chemoprevention
trials with the assumption that it could reduce oxidative
stress, which would contribute to genomic instability and
tumorigenesis. In fact, oral NAC 1800 mg daily could be
given to human subjects safely, with associated measur-
able reduction in markers of oxidation (Mantovani et al.,
2003). Disappointingly, however, NAC at 600 mg daily
over 2 years did not appear to have a measurable impactSIGNIFICANCE
The potential antitumorigenic effects of antioxidants have been the driving force for large chemoprevention clinical
trials as well as multiple studies in preclinical tumor models. Although the effect of antioxidants has been pre-
sumed to be mediated through squelching of reactive oxygen species and reducing genomic instability, the find-
ings of this study indicate that the antitumorigenic effect of antioxidants is dependent on the hypoxia-inducible
factor, HIF-1. Our observations provide mechanistic insights and suggest a therapeutic role for antioxidants
against HIF-1-dependent tumors.Inc.
Cancer Cell
Antitumorigenic Effect of Antioxidantsin patients with head and neck or lung cancer (Aitio, 2006).
Notwithstanding this specific outcome with NAC, antioxi-
dants continue to be of key interest for chemoprevention
(Narayanan, 2006). The combination of tumorigenic ani-
mal models that respond to antioxidants, the effects of an-
tioxidants on oxidative DNA damage, the contribution of
DNA damage to genomic instability, and the contribution
of genomic instability to tumorigenesis has resulted in
the paradigm that antioxidants could diminish tumorigen-
esis by decreasing oxidative DNA damage and genomic
instability. This notion in part originated from the initial
claim from the 1970s that vitamin C is an effective cancer
therapeutic (Cameron et al., 1979), but experimental
mechanistic evidence for the antitumorigenic effects of
antioxidants has not been well established. We have
also observed that both NAC and vitamin C have signifi-
cant antitumorigenic effects in vivo, but in stark contrast
to conclusions made from earlier studies, we found that
their effects are highly dependent on hypoxia-inducible
factor 1 (HIF-1) rather than on reduction of genomic insta-
bility in a MYC-dependent lymphoma model.
Since Myc has also been tightly linked to generation of
ROS, promotion of genomic instability, and tumorigenesis
(Vafa et al., 2002), we sought to determine whether NAC
could diminish tumorigenesis in two MYC-dependent
models and one MYC-independent model. We sought to
determine the potential role of ROS in Myc-induced tu-
morigenesis and genomic instability and found that the
antioxidant NAC could dramatically diminish tumorigene-
sis of P493 human B cell xenografts in SCID mice as well
as inhibit a Myc-dependent transgenic model of hepato-
cellular carcinoma. We had expected that tumors arising
in the xenografts would display genomic instability as
seen in the transgenic murine lymphoma models but
found through the use of spectral karyotyping and 300K
SNP genotyping that very few changes could be detected
at this level of resolution. These findings suggest that the
antitumorigenic effects of NAC are not due to a diminution
of genomic instability and led us to seek another mecha-
nism. Because of the dramatic phenotypic effects of NAC,
we sought to determine whether tumor adaptation to the
microenvironment could be affected, as the stability of
HIF-1 is dependent on ROS metabolism.
The activation of HIF-1, a transcription factor that is sta-
bilized in response to hypoxia, significantly contributes to
the induction of VEGF for angiogenesis and the conver-
sion of glucose to lactate for tumor glucose metabolism.
HIF-1 consists of an oxygen-sensitive HIF-1a subunit
that heterodimerizes with the HIF-1b subunit to bind
DNA. In high oxygen tension, HIF-1a is hydroxylated by
prolyl hydroxylases (PHDs) using a-ketoglutarate derived
from the Krebs cycle. The hydroxylated HIF-1a subunit
is ubiquitylated by the von Hippel-Lindau protein, VHL,
and destined for degradation by proteasomes, such that
HIF-1a is continuously synthesized and degraded under
nonhypoxic conditions (Semenza, 2003). In hypoxia,
HIF-1a remains unhydroxylated, thereby stabilizing HIF-1.
HIF-1 in turn directly transactivates glycolytic enzyme
genes and VEGF. Hence, adaptation to the hypoxic tumorCancmicroenvironment results in increased glucose uptake
and lactate production and angiogenesis.
There are several isoforms of PHDs, with PHD2 playing
the most critical role in hydroxylating HIF-1a (Berra et al.,
2003; Brahimi-Horn et al., 2007). Over the last several
years, the connection between mitochondrial ROS pro-
duction, hypoxia, and HIF-1 stabilization has emerged.
In contrast to expectation, hypoxia or limited oxygen in-
creases mitochondrial ROS rather diminishes it (Kaelin,
2005b). ROS, in turn, inactivates PHD2 and hence stabi-
lizes HIF-1a. ROS inactivates PHDs through oxidation of
the ferrous ion that is central and essential for the catalytic
hydroxylation of prolines. Vitamin C has been shown to
decrease HIF-1 levels by preventing the oxidation of the
catalytic ferrous ion (Lu et al., 2005). Whether the antitu-
morigenic effects of vitamin C and NAC are attributable
to the prevention of genomic instability or adaptation to
the tumor microenvironment has not been established
(Cameron et al., 1979; Pauling et al., 1985). We report
here substantial evidence favoring the latter—that the
antitumorigenic effects of NAC and vitamin C in Myc-
mediated tumorigenesis are indeed HIF-1 dependent.
These unexpected findings are likely to contribute signi-
ficantly to our understanding of the role of antioxidants
in tumorigenesis and perhaps give insight into novel
adjuvant therapies.
RESULTS AND DISCUSSION
We used the human P493 B cells that conditionally ex-
press MYC upon removal of tetracycline or doxycycline
(DOX) (see Figure S1A in the Supplemental Data available
with this article online) in a xenograft model in SCID mice
(Schuhmacher et al., 1999). NAC treatment administered
in the drinking water dramatically decreased lymphoma-
genesis, which was suppressed by doxycycline-induced
repression ofMYC (Figures 1A and 1B). In contrast to tet-
racycline, NAC neither inhibits the expression of Myc pro-
tein nor the growth of P493 cells in vitro (Figure S1B and
data not shown).
We also used TRE-LAPMYC transgenic mice that over-
express MYC in liver cells upon removal of DOX from the
drinking water (Beer et al., 2004). As reported previously,
we observedMYC overexpression and hepatocellular car-
cinoma (HCC) formation in neonates from untreated preg-
nant females. Neonates at 6 days of age demonstrated
HCC that occupied the entire liver, whereas neonates
from NAC-treated pregnant females did not develop
HCC by 11 days, when all untreated transgenic animals
had succumbed to HCC (Figures 1C and 1D). In this
model, the MYC transgene is induced nearly 10-fold in
nontumorous livers above doxycycline-treated controls;
however,MYC expression is further accentuated in tumor
cells through an unknown mechanism (Beer et al., 2004).
The livers of day 6 and older untreated neonates have
greater MYC expression (Figure 1E) because their livers
were infiltrated with tumor cells that have accentuated
MYC expression as compared with lowerMYC expression
in the NAC-treated nontumorous livers. It is notable that ater Cell 12, 230–238, September 2007 ª2007 Elsevier Inc. 231
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(A) Representative human P493 B cell tumors with tetracycline-repressible MYC marked with luciferase were imaged via a Xenogen instrument at
day 10. Animals received normal water (Untreated) or water containing 40 mM N-acetylcysteine (NAC) or 0.01% (w/v) doxycycline (+DOX).
(B) Tumor volumes (mean ± SD)measured by caliper at 2 weeks of a cohort of animals, including ones shown in (A). Ten animals treatedwith both NAC
and DOX displayed no tumors (data not shown).
(C) RepresentativeMYC-inducible neonatal hepatocellular carcinomas in the absence of doxycycline (Untreated) are evident through gross hepato-
megaly, which was not observed in either doxycycline (+DOX) or NAC-treated 11-day-old animals.
(D) Representative hematoxylin-and-eosin-stained histological sections of livers from untreated, DOX-, or NAC-treated 8-day-old neonates (originally
203 magnification).
(E) At least ten animals in each untreated, doxycycline (DOX)-, or NAC-treated group are shown with the corresponding liver-to-body-mass ratio
(upper panel) or Myc mRNA level (lower panel). Mouse age is indicated in the bottom of the lower panel.neonatal day 3, when the livers have not developed tu-
mors, NAC does not affect the expression of MYC, while
DOX treatment abolished MYC expression (Figure 1E).
Hence, NAC neither directly affected the expression of
MYC in the human P493 B cells (Figure S1B) nor in the
MYC-dependent liver cancer model.
From the twomodels, which both displayed remarkable
responses to NAC treatment, we selected the experimen-
tally more tractable human P493 B cells to delineate the
mechanism of NAC action. We first determined whether
genomic instability is involved in P493 lymphomagenesis
and tested the hypothesis that Myc induction of ROS
and DNA damage (Figure S1A and S1C) would contribute
to chromosomal instability and tumor progression in vivo
as seen in murine models (Karlsson et al., 2003; Limoli
et al., 2003; Louis et al., 2005; Sander et al., 2005). We
note that NAC diminishesMYC-induction of ROS produc-
tion and phosphorylated histone H2AX, which serves as
a surrogate marker of transient DNA damage (Figures
S1B and S1C). We compared the genomes of B cells
grown in vitro with those recovered from the xenografts.
We found no significant genomic instability through spec-
tral karyotyping (Figure S1D), high-density SNP analysis,
or array comparative genomic hybridization (Figures S1E
and S1F), implying that the effect of NAC could not be
attributed to diminished chromosomal instability. In fact,
although p53 was implicated in ROS-induced genomic232 Cancer Cell 12, 230–238, September 2007 ª2007 Elsevier Ininstability, a recent study suggests that p53-mediated tu-
mor suppression is independent of its ability to guard the
genome (Christophorou et al., 2006). Moreover, the low
level of chromosomal instability of our in vivo human B
cell tumor model (see Supplemental Data) is consistent
with the low level of genomic changes in primary human
Burkitt’s lymphomas, which are characterized by chromo-
somal translocations involving MYC, as compared with
diffuse large B cell lymphomas (Hummel et al., 2006).
Earlier studies have suggested that ROS levels are es-
sential for the stability of HIF-1, which has emerged at
the crossroads of many tumorigenic pathways via its abil-
ity to regulate genes involved in angiogenesis, glycolysis,
and mitochondrial function (Brunelle et al., 2005; Covello
and Simon, 2004; Giaccia et al., 2003; Guzy et al., 2005;
Kaelin, 2005b; Pouyssegur et al., 2006; Semenza, 2003;
Zhang et al., 2007). Hence, we reasoned that NAC, an
ROS scavenger, could possibly inhibit HIF-1 activity by
neutralizing ROS and thereby attenuate tumorigenesis.
HIF-1 is a heterodimeric transcription factor composed
of HIF-1b and HIF-1a. Proline residues 402 and 564 are
hydroxylated by PHD, a modification that marks HIF-1a
for recognition by the VHL protein, ubiquitination, and
subsequent degradation by proteasomes (Kaelin,
2005a). Similar to the antioxidant ascorbate (vitamin C),
which was reported to decrease HIF-1a levels by main-
taining the catalytic ferrous ion of PHD in the reducedc.
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HIF-1 Levels and Activity
(A) Immunoblots of HIF-1a protein levels in hu-
man P493 B cells grown in 20% or 1% oxygen
in the presence or absence of 10mMN-acetyl-
cysteine (NAC) and the tubulin loading control
are shown. Cells were treatedwith NAC or sub-
jected to hypoxia for 24 hr before analysis.
(B) NAC (10 mM) treatment for 24 hr does not
affect HIF-1a mRNA levels (mean ± SD) in
P493 cells.
(C) VEGF secreted into conditioned P493
media is markedly diminished by NAC, which
does not directly inhibit the VEGF immunoas-
say in vitro. ELISA results (mean ± SD) for du-
plicate measurements from four independent
experiments are shown.
(D) Immunoblot of HIF-1a induced in hypoxic
(1% oxygen for 8 hr) human prostate carci-
noma PC3 cell line bearing an HRE-driven
green fluorescent protein (GFP) reporter
demonstrates the inhibitory effect of NAC on
HIF-1a level.
(E) Flow cytometric analysis of GFP expression
demonstrates induction of the HRE-responsive reporter in 1% oxygen that is diminished by 10 mM NAC, illustrating the functional effect of NAC on
HIF-1a level and the reporter in the same cell line. (Left panel) Dot plots represented by FL.1 and FL.2 parameters indicate the negative and positive
PC3 cells expressing GFP. FL.1 represents a channel over the GFP emission spectrum peak, whereas FL.2 is a channel set over higher wavelengths
providing an irrelevant parameter used to complete a display of the data in two dimensions. (Right panel) Percent GFP fluorescence detected under
1% hypoxia over that at 20% oxygen in the presence or absence of 10 mM NAC.active state, we hypothesize that NAC might also activate
PHDs, thereby decreasing HIF-1a levels (Knowles et al.,
2003; Lu et al., 2005).
To test whether NAC could decrease HIF-1a, we stud-
ied human P493 B cells, which lack HIF-2a expression
(Figure S2). Treatment of hypoxic (1% oxygen) P493 cells
with NAC diminished the level of HIF-1a protein
(Figure 2A). The level of VEGF, a target of HIF-1 regulation,
was also significantly diminished by NAC in four indepen-
dent experiments (Figure 2C). The effect of NAC onHIF-1a
levels was also observed in the human prostate carci-
noma cell line PC3, which has been engineered to contain
a GFP reporter responsive to HIF-1 through hypoxia
response elements (Figures 2D and 2E) (Raman et al.,
2006). Both HIF-1a level and the reporter activity were
diminished by NAC, indicating that the effects are not re-
stricted to human B cells. Because NAC did not affect
HIF-1amRNA levels in P493 cells (Figure 2B), we hypoth-
esize that NAC induces HIF-1a degradation as previously
observed with ascorbate (Lu et al., 2005).
Because HIF-1a levels are regulated by PHDs that mark
HIF-1a for recognition by VHL and target it for proteasomal
degradation,we sought to determinewhether the effects of
NAC on HIF-1a levels are dependent on PHDs and VHL.
First, we examined the effects of NAC on a HIF-1amutant,
CA5, which has been rendered resistant to proteasomal
degradation via deletion of part of the oxygen-dependent
domain of HIF-1a and mutation of specific prolyl residues
(Kelly et al., 2003). When P493 cells that ectopically
expressedCA5were treatedwithNAC, under hypoxic con-
ditions, the levels of endogenous HIF-1a were reduced,
whereas CA5 levels were unaffected (Figure 3A).CanceTo determine the role of prolyl hydroxylation in the sen-
sitivity of HIF-1a to NAC, we tested a FLAG-tagged HIF-1a
with prolyl mutations P402A and P564A in comparison to
the tagged wild-type HIF-1a (Liu et al., 2007). As shown in
Figure 3B, the HIF-1a P402A/P564Amutant was resistant,
while the wild-type HIF-1a was sensitive to NAC treat-
ment. Furthermore, cells were transfected with siRNA tar-
geting either PHD1 or PHD2. The expression of HIF-1a
was increased in PHD2 siRNA-treated cells but not af-
fected in PHD1 siRNA-treated cells under nonhypoxic
condition (Figure 3C and Figure S3), confirming earlier re-
ports that PHD2 but not PHD1 is involved in HIF-1a degra-
dation (Berra et al., 2003). Importantly, NAC did not
decrease the expression of HIF-1a in PHD2 knockdown
cells, indicating that the NAC effect is dependent on
PHD2. We also examined the effect of NAC on HIF-1a
levels in the RCC4 renal carcinoma cell line that lacks
VHL and a derivative line with reconstituted VHL expres-
sion (Figure 3D) (Hu et al., 2003). While the constitutively
elevated level of HIF-1a in the VHL-deficient parental
RCC4 cells was not sensitive to NAC, hypoxia-induced
HIF-1a (and HIF2a; see Figure S2) levels in the VHL-recon-
stituted RCC4 cells was fully sensitive to NAC treatment.
These observations support the hypothesis that NAC di-
minishes HIF-1a levels by stimulating HIF-1a degradation
in a PHD2- and VHL-dependent manner.
To determine whether the antitumorigenic effect of NAC
in vivo is HIF-1a dependent, we tested the tumorigenic po-
tential of P493 cells ectopically expressing the stabilized
HIF-1a mutant CA5 (Kelly et al., 2003). As compared
with control transduced P493 cells, the CA5-expressing
cells display a significant degree of resistance to NACr Cell 12, 230–238, September 2007 ª2007 Elsevier Inc. 233
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HIF-1 Is Dependent on PHD2 and VHL
(A) Immunoblot of endogenous HIF-1a and the
HIF-1 CA5 mutant in CA5 or control (Cont)
hypoxic P493 cells untreated (Untreated) or
treated with 10 mM N-acetylcysteine (NAC).
Tubulin serves as a sample loading control.
(B) P493-6 cells were transfected with expres-
sion vectors encoding wild-type FLAG-HIF-1a
or FLAG-HIF-1a (P402A/P564A) by using the
Amaxa Nucleofector system. After 24 hr, cells
were cultured with or without 10 mM NAC
under 1% O2 for an additional 24 hr. Cells
were then lysed and immunoblotted with anti-
FLAG antibody. Tubulin was also immunoblot-
ted in the samemembrane as a loading control.
(C) The P493 cells overexpressing CA5 were
untreated or treated with siRNAs against prolyl
hydroxylases PHD1 or PHD2. Immunoblots of
HIF-1 (HIF-1a and CA5), PHD1, PHD2, and tu-
bulin are shown. Note that CA5 is constitutively
expressed while endogenous HIF-1a is ex-
pressed only in PHD2 siRNA-treated cells in
a manner that is not affected by NAC.
(D) RCC4 cells lacking VHL or reconstituted
with VHL (RCC4 + VHL) were grown in 20% or
1% oxygen in the presence or absence of 10
mM NAC.treatment, with only a slight decrease in tumor size (Fig-
ures 4A and 4B), which may be due to effects of NAC on
tumor stromal cells that do not express CA5. The resis-
tance of the CA5 tumors to NAC is not due to the inability
of NAC to permeate the tumors, because the levels of en-
dogenous HIF-1a in the tumors are dramatically reduced
by NAC treatment (Figure 4C). In addition to the effects
of NAC, ascorbate also effectively inhibited P493 lympho-
magenesis, whereas P493 cells overexpressing CA5
showed significant resistance to the effects of ascorbate
(Figure 5).234 Cancer Cell 12, 230–238, September 2007 ª2007 Elsevier ITo determine the necessity of HIF-1a for P493 tumori-
genesis, we used shRNA to reduce HIF-1a levels and
found that tumorigenesis is profoundly inhibited with di-
minished HIF-1a (Figure 6). Thus, the reduction of HIF-1a
expression, as occurs in response to NAC, is sufficient to
inhibit MYC-mediated tumorigenesis. It is notable that
while HIF-1a could negate and HIF-2a could stimulate
endogenousMyc function, the stoichiometric overexpres-
sion of Myc in P493 cells (which do not express HIF-2a)
can override the HIF-1 interaction network that attenuates
endogenous Myc protein function (Gordan et al., 2007;Figure 4. P493 Tumors Expressing the
Stabilized HIF-1a Mutant CA5 Resist the
Antitumorigenic Effect of N-Acetylcys-
teine
(A) In vivo bioluminescent images at day 10 of
representative CA5-overexpressing or control
(Cont) P493 B tumors untreated () or treated
(+) with NAC (40 mM in drinking water).
(B) Volumes measured by caliper of CA5-over-
expressing or control P493 B tumors untreated
or treated with NAC (n = 10 for each group;
mean ± SEM) are shown.
(C) (Left panel) Immunoblot of HIF-1 demon-
strates the hypoxic induction of endogenous
HIF-1a in both control and CA5-overexpress-
ing cells as compared with the constitutive
expression of CA5. (Right panel) Tumor cells
in xenografts recovered from control (–) or
NAC-treated (+) mice display constitutive
CA5 expression along with NAC-sensitive en-
dogenous HIF-1a expression.nc.
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Stabilized HIF-1a Mutant CA5 Resist the
Antitumorigenic Effect of Vitamin C
(A) Representative in vivo bioluminescent im-
ages of SCID mice xenografts of P493 cells
overexpressing the stabilized HIF-1 CA5 mu-
tant or control transduced P493 cells. Animals
were untreated or treated with ascorbate (ASC)
(5 g/liter in drinking water).
(B) Time-dependent tumor volumes deter-
mined by caliper in four groups of mice injected
with P493 cells overexpressing CA5 or control
cells and either untreated or treated with
ascorbate (ASC). Data are shown as mean ±
SEM.
(C) Immunoblot of HIF-1a in control P493 cells
or P493 cells expressing CA5 untreated or
treated with ascorbate (ASC). Endogenous
HIF-1a is shown with ectopic HIF CA5 mutant.Koshiji et al., 2004, 2005; Zhang et al., 2007). On the other
hand, HIF-1a is not sufficient for tumorigenesis, because
P493 xenografts expressing CA5 are completely sup-
pressible by doxycycline (data not shown). Xenografts of
the non-MYC-dependent human prostate cancer cell
line PC3, which expresses CA5, are also more resistant
to NAC treatment as compared to control transduced
PC3 cells (Figure 7). Collectively, these observations indi-
cate that an important antitumorigenic activity of the anti-
oxidants NAC and ascorbate is their ability to stimulate the
degradation of HIF-1.
Our findings do not rule outminor HIF-independent anti-
tumorigenic effects of antioxidants, but they challenge the
current paradigm that antioxidants inhibit tumorigenesis
predominantly by decreasing ROS-mediated DNA dam-
age and mutations (Poirier, 2004; Sharma and Farmer,
2004). Although ROS can induce genomic instability and
NAC can inhibit ROS, our results suggest that the antitu-
morigenic effect of NAC is derived predominantly from
its effect on HIF-1. If genomic instability induced by ROS
is the dominant factor in MYC-dependent P493 and
MYC-independent PC3 cell tumorigenesis, then the HIF-
1 mutant CA5 would not have overridden the effects of
NAC. We provide experimental evidence indicating
instead that CA5 could rescue tumorigenesis from the
effects of NAC and that increased HIF-1a degradation
represents a major molecular mechanism underlying theCancantitumorigenic effect of antioxidants. In particular, con-
sistent with recent findings that inactivation of PHD2 by
ROS produced by hypoxic cells increases HIF-1a levels
(Kaelin, 2005b), we found that the antioxidants NAC
and vitamin C decreased HIF-1a levels under conditions
in which HIF-1a was hydroxylated by PHD2 and ubiquiti-
nated byVHL.Hence, our findings not only uncover a basis
for the antitumorigenic effect of antioxidants, but they also
suggest the potential application of antioxidants for adju-
vant therapy to prevent progression or recurrence of HIF-
dependent tumors. We caution, however, that the doses
of antioxidants used in our mouse studies exceed those
currently used in the clinical setting, which may require
a much higher dose to affect tumors.
EXPERIMENTAL PROCEDURES
Cell Lines and Hypoxic Exposure
P493 human B cells and PC3-HRE-GFP cells (Raman et al., 2006) were
maintained in RPMI 1640 with 10% fetal bovine serum (FBS) and 1%
penicillin-streptomycin. VHL null RCC4 cell line and a derivative cell
line stably transfected with an expression vector encoding VHL,
RCC4-VHL (gift of Celeste Simon, University of Pennsylvania, Philadel-
phia, PA) (Hu et al., 2003), were maintained in high glucose (4.5 mg/ml)
DMEM with 10% FBS and 1% penicillin-streptomycin. P493-CA5
stable cells were generated by retroviral infection and selected with
800 mg/ml G418 as described previously (Krishnamachary et al.,
2006). Polyclonal pools of cells were used for experiments.Figure 6. HIF-1a Levels Are Necessary
for Myc-Induced P493 Tumorigenesis
(A) Reduction of HIF-1a levels in P493 cells by
stable shRNA expression as shown by immu-
noblotting. Control lysate (EV) is shown with
two independent pools of P493 cells trans-
duced with two different shRNAs (sh1718 and
sh2265) targeting HIF-1a.
(B) In vivo bioluminescent images of tumors
from control cells versus cells expressing
HIF-1a shRNA.
(C) Tumor growth of control and HIF-1a ex-
pressing P493 cells as determined by caliper
measurements (mean ± SEM; n = 5 for each
group).er Cell 12, 230–238, September 2007 ª2007 Elsevier Inc. 235
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the HIF-1a CA5 Mutant Are Relatively
Resistant to NAC Treatment
(A) Immunoblot of lysates from hypoxic (1%
oxygen) cells showing the expression of CA5
that is resistant to NAC-induced degradation.
Cells were treated with 10 mM NAC for 24 hr.
(B) Tumor growth of control PC3 cells or PC3
cells stably expressing the HIF-1a CA5 mutant
in response to NAC treatment (40 mM in drink-
ing water). Data are shown as mean ± SEM,
with n = 5 for each group.Nonhypoxic cells (20%O2) weremaintained at 37
C in a 5%CO2, 95%
air incubator. Hypoxic cells (1%O2) weremaintained in a controlled at-
mosphere chamber (PLAS-LABS, Lansing, MI) with a gas mixture con-
taining 1% O2, 5% CO2, and 94% N2 at 37
C for the indicated time.
Cells were exposed to hypoxia for 24 hr before analysis unless other-
wise indicated.
RNA Interference Experiments
siRNAs targeting human PHD1, PHD2 (siGENOME SMART POOL)
were purchased from Dharmacon Research Inc. Targeting sequences
for PHD1 were a pool of following eight sequences. Sense 1, GAACCA
GGCUGUCGAAGCAUU; antisense 1, 50-P-UGCUUCGACAGCCUGG
UUCUU; sense 2, AAUCAGAACUGGGACGUUAUU; antisense 2, 50-
UAACGUCCCAGUUCUGAUUUU; sense 3, CAACAUCGAGCCACUC
UUUUU; antisense 3, 50-AAAGAGUGGCUCGAUGUUGUU; sense 4,
ACAGAAAGGUGUCCAAGUAUU; antisense 4, 50-UACUUGGACACC
UUUCUGUUU. Targeting sequences for PHD2 were a pool of follow-
ing eight sequences. Sense 1, CAAGGUAAGUGGAGGUAUAUU; anti-
sense 1, 50-UAUACCUCCACUUACCUUGUU; sense 2, GCGAUAAG
AUCACCUGGAUUU; antisense 2, 5-AUCCAGGUGAUCUUAUCG
CUU; sense 3, GCUCAUCGCUGUUCCAGGAUU; antisense 3, 50-UCC
UGGAACAGCGAUGAGCUU; sense 4, GAACAAGCACGGCAUCUGU
UU; antisense 4, 50-ACAGAUGCCGUGCUUGUUCUU. Transfection of
siRNA was performed using an Amaxa Nucleotransfection device ac-
cording to the manufacturer’s instructions. Briefly, 100 nM PHD1,
PHD2 siRNAs or Risc-free control siRNA (Dharmacon Research Inc.)
were transfected into 2.5 3 106 P493 cells. After 48–72 hr, the cells
were treated with or without N-acetylcysteine for 24 hr and harvested
for the indicated assays. P493-HIF-1a shRNA stably transduced cells
(Polyclonal pools of P493-sh-1718 or P493-sh-2265) were generated
by retrovirus infection and G418 selection (800 mg/ml) as described
previously (Krishnamachary et al., 2006).
DNA Vectors and Transfection
Expression vectors encoding wild-type FLAG-HIF-1a or mutant FLAG-
HIF-1a (P402A/P564A) were described previously (Liu et al., 2007). The
Amaxa Nucleofector system was used for transient transfection of the
vectors into P463 cells (2 mg DNA, Kit V, 2.5 3 106 cells and program
O-006 were used for transfection).
Western Blot Analysis
We obtained mouse antibody for HIF-1a from BD-BioSciences Phar-
Mingen (Cat #610959), mouse antibody for HIF-2a from Santa Cruz
Biotechnology (Cat # SC-28706), rabbit antibody for PHD1 from Bethyl
Laboratories, Inc (Cat# A300-326A), rabbit antibody for PHD2 from
Abcom (Ab26058), mouse antibody (9E10) for c-Myc from Zymed
Inc., mouse antibody for phospho-Histone H2A-X from Upstate (Cat
#05-636), mouse antibody for tubulin from CalBiochem (Cat# CP06),
and performed western blot assay according to the manufacturer’s
instructions.
mRNA Quantitation (Real-Time PCR)
Total RNA was extracted using the RNeasy kit (QIAGEN) followed by
DNAase (Ambion) treatment according to the manufacturer’s instruc-236 Cancer Cell 12, 230–238, September 2007 ª2007 Elseviertions. Primers were designed using Beacon Designer software, and
cDNA was prepared using TaqMan Reverse Transcription Reagents
(Roche, Applied Biosystems). Quantitative real-time PCR for HIF-1a,
HIF-2a, or c-Myc was performed using the ABI 7700 sequence detec-
tion system. A predeveloped probe and primers specific to 18S
rRNA levels were used for normalization. All PCRs were performed in
triplicate.
Animal Studies
All mice were housed under pathogen-free conditions. The animal
studies were performed according to the protocols approved by the
Animal Care and Use Committee at Johns Hopkins University. For tu-
morigenesis study in a xenograft model, 30 3 106 P493-6 cells were
injected subcutaneously into SCID mice. A group of mice was treated
with 40 mM N-acetylcysteine (Sigma-Aldrich) or ascorbate (5 g/L) in
drinking water 7 days before tumor inoculation and throughout the
study. The amount of NAC administered daily is estimated at 1 g/kg.
The use of pharmacokinetics constant infusion calculation, assuming
a half-life of 2 hr for NAC, yielded a steady-state concentration of
9.2 mM or 1.5 g/L NAC for a 20 g mouse with a blood volume of
1.6 ml (note that this concentration is underestimated, since plasma
volume is only a fraction of blood volume).
The tumor volumes were measured using a caliber every 4 days and
calculated using the following formula: [length (mm) 3 width (mm) 3
width (mm) 3 0.52]. Early development of tumor was also monitored
by an in vivo Xenogen in vivo bioluminescent imaging system.
The conditional c-Myc-transgenic neonatal hepatocellular carci-
noma model was as described (Beer et al., 2004). The animals were
maintained on regular drinking water or water supplemented with
40 mM NAC or 0.01% doxycycline 2 weeks before mating of LAP-
tTA (liver specific expression of the tetracycline suppressible transac-
tivator) and TRE-Myc transgenic mice and throughout the study. Male
mice (in which the TRE-Myc transgene integrated into the Y chromo-
some) with both transgenes were studied. The formation of tumors
was monitored by daily inspection and confirmed by histological
examination.
Genomic Integrity Study
We compared the genomic integrity of the P493 cells grown in vitro
with those recovered from the xenografts of P493 cells. G-band anal-
ysis and SKY analysis of both cells were performed by Cytogenetics
Core Facility at Johns Hopkins. The high-density SNP analysis was
provided by the Johns Hopkins SNPCenter using Illumina’s BeadArray
technology (http://snpcenter.grcf.jhmi.edu/). Array comparative geno-
mic hybridization using Agilent microarrays and data analysis were
performed by Microarray Core Facility, Johns Hopkins Cancer Center.
In Vivo Imaging
Animals inoculated with P493 lymphoma cells, which were engineered
with a luciferase reporter gene, were anesthetized and injected intra-
peritoneally with 3 mg/200 ml luminescent substrate D-LuciferinFirefly
(XenoGEN Cat# XR-1001). The animals were then imaged and ana-
lyzed by using the Xenogen IVIS 200 Optical Imaging Device in the
Johns Hopkins Molecular Imaging Center.Inc.
Cancer Cell
Antitumorigenic Effect of AntioxidantsFlow Cytometry
For GFP detection in PC3-HRE reporter cells, cells were cultured in
a hypoxic chamber (1% oxygen) for 24 hr in the presence or absence
of 10 mM NAC. Cells were then washed and analyzed using a Becton
Dickinson FACSCalibur flow cytometer. Cells cultured under normoxic
conditions (20% O2) were used as control.
Immunoassay for Human VEGF
VEGF concentration in cell culture supernatants was measured by us-
ing an immunoassay kit from R&D Systems (Quantikine Cat#DVE00)
according to the manufacturer’s instruction. The data were normalized
using the human VEGF standard curve provided by the immunoassay
kit.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.cancercell.org/cgi/content/full/12/3/230/DC1/.
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